Copy
Anatara Lifesciences email update 17/07/19
View this email in your browser


Pitt Street Research Report


BRISBANE, July 17, 2019
 
Pitt Street Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a $1.09/share base case and $3.20/share optimistic case valuation range.

"Detach upside remains”
Key Points
  • Anatara can still find a good partner for lead animal health product, Detach - the company has several other options in the medium to long term
    • Anatara had engaged with over 10 top multinational animal health companies prior to signing an agreement with Zoetis
  • There remains considerable upside from a human health application - Anatara’s bromelain-based Gastrointestinal ReProgramming (GaRP) product
    • Anatara’s current cash is sufficient to fund GaRP in the human GI space through to the point of licensing out.
    • Milestones and royalty payments will provide funding for future developments
    • Due to the regulatory and commercial advantages associated with natural products and the complexity of management of IBS and IBD, GaRP has significant upside potential.
Please click here to view the report.

Copyright © 2019 Anatara Lifesciences Ltd, All rights reserved.


unsubscribe from this list    update subscription preferences